- Home
- TLPH vs NERV Comparison
TLPH vs NERV Comparison
Compare TLPH & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- NERV
- Stock Information
- Founded
- TLPH 2005
- NERV 2007
- Country
- TLPH United States
- NERV United States
- Employees
- TLPH N/A
- NERV N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- NERV Health Care
- Exchange
- TLPH Nasdaq
- NERV Nasdaq
- Market Cap
- TLPH 10.6M
- NERV 12.6M
- IPO Year
- TLPH 2011
- NERV 2014
- Fundamental
- Price
- TLPH $0.44
- NERV $1.77
- Analyst Decision
- TLPH Strong Buy
- NERV Hold
- Analyst Count
- TLPH 1
- NERV 1
- Target Price
- TLPH $6.00
- NERV $5.00
- AVG Volume (30 Days)
- TLPH 31.7K
- NERV 13.4K
- Earning Date
- TLPH 08-13-2025
- NERV 08-05-2025
- Dividend Yield
- TLPH N/A
- NERV N/A
- EPS Growth
- TLPH N/A
- NERV N/A
- EPS
- TLPH N/A
- NERV 0.83
- Revenue
- TLPH $27,000.00
- NERV N/A
- Revenue This Year
- TLPH N/A
- NERV N/A
- Revenue Next Year
- TLPH $14,533.26
- NERV N/A
- P/E Ratio
- TLPH N/A
- NERV $2.17
- Revenue Growth
- TLPH N/A
- NERV N/A
- 52 Week Low
- TLPH $0.44
- NERV $1.15
- 52 Week High
- TLPH $1.19
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- TLPH 31.91
- NERV 55.49
- Support Level
- TLPH $0.45
- NERV $1.62
- Resistance Level
- TLPH $0.52
- NERV $1.87
- Average True Range (ATR)
- TLPH 0.03
- NERV 0.11
- MACD
- TLPH -0.00
- NERV 0.00
- Stochastic Oscillator
- TLPH 0.00
- NERV 55.93
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.